The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary
Gonzales, D., S. I. Rennard, M. Nides, C. Oncken, S. Azoulay, C. B. Billing, E. J. Watsky, J. Gong, K. E. Williams, and K. R. Reeves. 2006. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association 296(1):47-55.
Harris, L., H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast, Jr. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of ClinicalOncology 25(33):5287-5312.
Imperiale, T. F., D. R. Wagner, C. Y. Lin, G. N. Larkin, J. D. Rogge, and D. F. Ransohoff. 2000. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. New England Journal of Medicine 343(3):169-174.
Imperiale, T. F., E. A. Glowinski, C. Lin-Cooper, G. N. Larkin, J. D. Rogge, and D. F. Ransohoff. 2008. Five-year risk of colorectal neoplasia after negative screening colonoscopy. New England Journal of Medicine 359(12):1218-1224.
IOM (Institute of Medicine). 2010. The value of genetic and genomic technologies: Workshopsummary. Washington, DC: The National Academies Press.
IOM. 2011. Establishing precompetitive collaborations to stimulate genomics-driven productdevelopment: Workshop summary. Washington, DC: The National Academies Press.
Jarvinen, H. J., M. Aarnio, H. Mustonen, K. Aktan-Collan, L. A. Aaltonen, P. Peltomaki, A. D. L. Chapelle, and J. P. Mecklin. 2000. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829-834.
Lee, J. J., and E. Chu. 2007. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clinical Colorectal Cancer 6 (Suppl 2):S42-S46.
Levin, L., R. Goeree, N. Sikich, B. Jorgensen, M. C. Brouwers, T. Easty, and C. Zahn. 2007. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: The Ontario experience. International Journal of TechnologyAssessment in Health Care 23(3):299-309.
Malaiyandi, V., S. D. Goodz, E. M. Sellers, and R. F. Tyndale. 2006. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiology, Biomarkers & Prevention 15(10):1812-1819.
Marchionni, L., R. F. Wilson, S. S. Marinopoulos, A. C. Wolff, G. Parmigiani, E. B. Bass, and S. N. Goodman. 2008. Impact of gene expression profiling tests on breast cancer outcomes. Evidence report/technology assessment no. 160. (prepared by the Johns Hopkins University Evidence-Based Practice Center under contract no. 290-02-0018). Agency forHealthcare Research and Quality Publication No. 08-E002 January.
Moss, A. J., W. Shimizu, A. A. Wilde, J. A. Towbin, W. Zareba, J. L. Robinson, M. Qi, G. M. Vincent, M. J. Ackerman, E. S. Kaufman, N. Hofman, R. Seth, S. Kamakura, Y. Miyamoto, I. Goldenberg, M. L. Andrews, and S. McNitt. 2007. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 115(19):2481-2489.
Paik, S., S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F. L. Baehner, M. G. Walker, D. Watson, T. Park, W. Hiller, E. R. Fisher, D. L. Wickerham, J. Bryant, and N. Wolmark. 2004a. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351(27):2817-2826.